Phase 4 Completed N=50 Randomized Triple-blind Treatment

Hip Fracture Exparel Administration Trial Capsule During Hemiarthroplasty

Intracapsular Fracture of Femur · Femoral Neck Fractures · Hip Hemiarthroplasty

Source: ClinicalTrials.gov NCT03502018 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Nov 2023

Primary outcomePrimary: Post-operative Pain — 3.29; 2.64 score on a scale

◆ Published Evidence

No publication linked

No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.

Summary

This study will examine the efficacy of Liposomal Bupivacaine (Exparel) in hip fracture patients undergoing hip hemiarthroplasty for femoral neck fractures through a posterior approach. Post-operative measures will be assessing pain, overall opiate use, delirium, time-to-ambulation and discharge status.

Outcome Measures

Outcome	Result	p-value
PRIMARY Post-operative Pain	2.71; 2.04	—
SECONDARY Time to Ambulation	1.44; 1.12	—
SECONDARY Postoperative Total Morphine Equivalent	9.98; 12.09	—
SECONDARY Delirium Scale Measurements	0; 1; 0; 0; 24; 24	—
SECONDARY Length of Stay	3.88; 3.92	—

Eligibility Criteria

Inclusion Criteria

Men and women sixty-five years of age and older with isolated intracapsular hip fractures undergoing hemi arthroplasty through a posterior approach with the ability to consent to the study.

Exclusion Criteria

Under sixty-five years of age, extracapsular hip fracture, suffer from any form of cognitive compromise that leaves them unable to consent, or if they are treated with any surgical modality other than hip hemiarthroplasty.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03502018). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.